Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

× No keyword cloud information.

33 in total

Review 1. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

Authors: L A Pagliaro; L Z Benet
Journal: J Pharmacokinet Biopharm Date: 1975-10

2. Antagonism of fludrocortisone by spironolactone and canrenone.

Authors: G J Huston; P Turner
Journal: Br J Clin Pharmacol Date: 1976-02 Impact factor: 4.335

3. Canrenoate disposition in dogs. Tissue distribution and elimination.

Authors: J Kuhlmann; V Kötter; N Rietbrock
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1977-06 Impact factor: 3.000

4. Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.

Authors: U Abshagen; H Rennekamp; J Kuhlmann
Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 1976 Impact factor: 3.000

5. Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

Authors: Maysa Suyagh; Ahmed F Hawwa; Paul S Collier; Jeffrey S Millership; Prashant Kole; Muriel Millar; Mike D Shields; Henry L Halliday; James C McElnay
Journal: Br J Clin Pharmacol Date: 2012-11 Impact factor: 4.335

6. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

Authors: Amitava Dasgupta; Myrtle J Johnson; Tamal K Sengupta
Journal: J Clin Lab Anal Date: 2012-05 Impact factor: 2.352

Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans.

Review 1. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.

2. Antagonism of fludrocortisone by spironolactone and canrenone.

3. Canrenoate disposition in dogs. Tissue distribution and elimination.

4. Effects of pretreatment with spironolactone of pharmacokinetics of 4'''-methyldigoxin in man.

5. Population pharmacokinetic model of canrenone after intravenous administration of potassium canrenoate to paediatric patients.

6. Clinically insignificant negative interferences of spironolactone, potassium canrenoate, and their common metabolite canrenone in new dimension vista LOCI digoxin immunoassay.

7. Canrenone--the principal active metabolite of spironolactone?

8. [Relative bioavailability in man of 2 pharmaceutical forms of canrenone].

9. A comparison of some extra-renal effects of spironolactone and canrenone.

10. Improved method for comparative evaluation of aldosterone antagonists in healthy man.